Plus, news about Takeda, Foresee Pharmaceuticals and Capricor Therapeutics:
GSK, Cambridge University team up on immune diseases: The UK drugmaker is pouring £50 million ($65 million) into a five-year partnership with the university and its hospitals to advance R&D for respiratory and kidney disease treatments. The collaboration will make use of AI and machine learning, with a focus on traditionally challenging indications. — Ayisha Sharma
Angelini Pharma signs licensing deal with Korean biotech: The deal covers a Cureverse program called CV-01, which is an Nrf2 agonist designed to treat “a range of brain health disorders, including epilepsy.” Cureverse will get an undisclosed upfront payment and can receive up to $360 million in milestones as well as additional royalties. The deal covers global rights outside of South Korea, China, Hong Kong, Macau and Taiwan. — Max Gelman
Takeda announces more layoffs in Massachusetts: The workforce reduction will impact 45 employees in Cambridge and 34 in Lexington, according to a WARN notice filed last week. Takeda has already laid off hundreds of employees in the state this year, including 641 in May and another 220 in July. The company declined to comment on the types of roles impacted. — Nicole DeFeudis
Foresee Pharmaceuticals touts early topline data for MMP-12 inhibitor: Healthy patients taking the inhibitor, called linvemastat, saw no serious adverse events, and the most common treatment-emergent adverse events were mild nausea and headaches. The company expects to start Phase 2 studies in asthma and inflammatory bowel disease next year. — Katherine Lewin
Capricor Therapeutics brought in $86.3 million from a public offering, up from the $75 million it planned to raise. — Jaimy Lee